オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; maize starch; povidone; crospovidone; stearic acid; colloidal anhydrous silica - codalgin forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: potassium sorbate; maize starch; povidone; purified talc; stearic acid; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch - apx-paracetamol/codeine is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

haleon ireland limited - paracetamol; codeine phosphate hemihydrate - film-coated tablet - 500/12.8 milligram(s) - codeine and paracetamol

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 30 mg - tablet - excipient ingredients: magnesium stearate; stearic acid; povidone; pregelatinised maize starch - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

chefaro ireland dac - paracetamol; codeine phosphate hemihydrate; caffeine - effervescent tablet - 500 mg/8 mg/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

chefaro ireland dac - paracetamol; codeine phosphate hemihydrate - film-coated tablet - 500 mg/12.8 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - paracetamol; caffeine - oral tablet - 500mg ; 65mg

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - paracetamol; codeine phosphate hemihydrate; doxylamine succinate; caffeine - film-coated tablet - 450mg/10mg/5mg/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet - excipient ingredients: magnesium stearate; povidone; pregelatinised maize starch; stearic acid - gppl paracetamol codeine 500/30 is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

lannett company, inc. - codeine sulfate (unii: 11qv9bs0cb) (codeine anhydrous - unii:ux6owy2v7j) - codeine sulfate 15 mg - codeine sulfate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [ s ee warnings and precautions ( 5.1 ) ] , reserve codeine sulfate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated. have not been tolerated, or are not expected to be tolerated. - have not provided adequate analgesia, or are not expected to provide adequate analgesia. have not provided adequate analgesia, or are not expected to provide adequate analgesia. codeine sulfate tablets are contraindicated for: - all children younger than 12 years of age [see warnings and precautions ( 5.4 )] . - post-operative management in children younger than 18 years of age following tonsillect